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A significant proportion of patients with chronic urticaria respond inadequately to first line treatment with
antihistamines. Leukotreine receptor antagonists (LTRA) are also used for chronic urticaria, although firm
recommendations on their use are lacking. We performed a systematic review of randomised trials to determine
the role of LTRA in treatment of chronic urticaria. A search of PUBMED, EMBASE, SCOPUS, LILACS, the Cochrane
Central Register of Controlled Trials, and the Web of Science for relevant randomized control trials or cross over
studies yielded 10 eligible studies. The heterogeneity of trials were high, preventing valid meta-analysis of data.
Most trials indicated that LTRA are not superior to placebo or antihistamine therapy, while combination therapy of
LTRA and antihistamines appear to be more efficacious compared to antihistamine alone. The side effect profile
and tolerability of this group of drugs is acceptable. The use of LTRA as monotherapy cannot be recommended.
LTRA are effective add-on therapy to anti-histamines, and their use in patients responding poorly to antihistamines
is justifiable. Further well designed randomized controlled trials with clear and standardized outcome measures are
needed to determine the role of LTRA in chronic urticaria.
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Urticaria (hives) is a condition characterized by superficial
skin weals and pruritus. Classically, chronic urticaria is de-
fined as the daily, or almost daily, occurrence of urticarial
weals for at least 6 weeks, without any physical, allergic, in-
fectious, drug-related or vasculitic cause [1,2]. In the past,
chronic urticaria was divided into two types, i.e., chronic
autoimmune urticaria and chronic idiopathic urticaria [3].
The current classification defines these as chronic spontan-
eous urticaria (CSP), characterised by the occurrence of
spontaneous weals and/or angio-oedema for longer than
6 weeks [4]. Several chemical mediators such as hista-
mines, leukotrienes, prostaglandins and cytokines secreted
by mast cells and basophils are involved in the pathogen-
esis of urticaria [5]. However, the routine treatment of
autoimmune and non-autoimmune chronic urticaria is
similar [1,2,6].* Correspondence: senaka.ucfm@gmail.com
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unless otherwise stated.A step-wise approach to treatment is currently advo-
cated in the EAACI/GA2LEN/EDF/WAO 2009 treatment
guidelines [7]. First line therapy is with a non-sedating H1-
antihistamine at standard doses. If no response is seen
after two weeks, the dose is increased up to four times the
standard or licensed dose. The addition of a leukotriene
receptor antagonist (LTRA) is recommended as third line
treatment. For severe or resistant cases, immunosuppres-
sants such as ciclosporin, dapsone, H2-antihistamines and
omalizumab [8] are also used. Short-course systemic
steroids are recommended for exacerbations.
Cysteinyl leukotrienes are potent pro-inflammatory medi-
ators whose effect can be blocked by LTRA such as monte-
lukast, zafirlukast and pranlukast. The benefit of these
drugs in patients suffering from asthma and allergic rhinitis
is well established, and current evidence clearly justifies
their use in those conditions [9]. Several recent studies have
addressed the use of these agents, as monotherapy as well
as in combination with other first line therapies, for chronic
urticaria. Nonetheless, there is controversy as to the efficacy
of LTRA for this indication; a previous review of six rando-
mised clinical trials comparing the use of montelukastl Ltd. This is an Open Access article distributed under the terms of the Creative
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mines concluded that the presence of contradictory results
makes the recommendation of montelukast for treating
chronic urticaria not justifiable [10]. Another systematic
review on the subject which included several case-series,
open-labelled studies and randomised controlled trials also
concluded that LTRA are not beneficial alone or in com-
bination with antihistamines in patients with idiopathic
chronic urticaria, although benefit was seen in patients
with food additive hypersensitivity and NSAID-exacerbated
chronic urticaria [11].
Evidence from new trials have been published since then.
In this context it is timely to evaluate the evidence from
randomized control trials on this subject, in order to pro-
vide an answer to the clinical question as to whether pre-
scribing LTRAs for chronic urticaria is justifiable. Hence,
we performed a systematic review of randomized controlled
trials examining the efficacy of LTRA either alone or in
combination with other drugs, compared with placebo or
antihistamines, for the treatment of chronic urticaria.
Review
Methods
Our aim was to include randomised controlled trials
(including cross-over studies) on patients with chronic
urticaria treated with LTRA alone or in combination with
antihistamines, compared with placebo or antihistamines
alone. We did not include physical urticaria as this is
thought to be pathophysiologically different [2]. We
searched MEDLINE, EMBASE, LILACS, Cochrane Central
Register of Controlled Trials (CENTRAL), Web of Science
and SCOPUS SciVerse for English language publications,
using the search terms ‘montelukast’ OR ‘*lukast’ OR ‘zafir-
lukast’ OR ‘leukotriene’ AND ‘urticaria’ in title, abstract,
keywords or topic with no date limits. The reference lists
were imported into ENDNOTE X5®, and duplicates were
removed. Two reviewers independently evaluated the
abstracts of all retrieved publications and selected studies
likely to provide relevant data. Full texts of selected publica-
tions were retrieved, and the two reviewers independently
read through the full texts. Mean difference was used as the
effect measure and 95% confidence interval was taken as
the level of significance.
Our search hits were as follows: combined search of
MEDLINE and EMBASE = 103, Web of Science = 220,
Scopus SciVerse = 846, CENTRAL = 31, LILACS = 217.
After filtering, we identified 13 randomised controlled
trials (RCT) which provided relevant data, and all were in-
cluded in the systematic review. Two studies evaluated the
role of LTRA in delayed pressure urticaria, and were ex-
cluded. Another study which evaluated the role of LTRA
in food additive hypersensitivity was excluded, thus leaving
10 trials for the final analysis. We obtained the full texts in
9, and the other was published only in abstract form [12].Results
Selected studies had comparisons of LTRA vs. placebo,
LTRA vs. antihistamines, and combination therapy (LTRA
plus antihistamines) vs. antihistamines alone. There was
much variation in the outcome measures studied; these in-
cluded different types of scores, marked either by the inves-
tigator or the patient, pertaining to clinical improvement of
urticaria, pruritus, number of hives, size of largest hives,
effect on daily activities and sleep. Total Symptom Score
(TSS) [13,14], Urticarial Activity Score (UAS) [15], use of
rescue medication and the visual analogue scale were con-
sidered as outcomes of overall improvement (Table 1).
Tolerability and safety of the treatments were assessed based
on symptomatology and changes in laboratory parameters.
The heterogeneity of the studies was too high to perform
pooling of data and valid meta-analysis. There were no stud-
ies evaluating the role of LTRA in angio-oedema per se.
LTRA vs. placebo
Di Lorenzo et al. [13] conducted a well-designed RCT of
160 adult (age 18–69 years) patients with chronic idio-
pathic urticaria, comparing four parallel groups receiving
desloratadine 5 mg daily, desloratadine 5 mg daily plus
montelukast 10 mg daily, montelukast 10 mg daily, and
placebo. Patients with drug or food induced urticaria, phys-
ical urticaria, and urticaria-vasculitis were excluded. Treat-
ment was given for 6 weeks, with assessment at 3 and
6 weeks and 2 weeks after completing treatment. Symp-
toms were scored daily, using reflective and instantaneous
assessment. Compliance was better in patients randomized
to desloratadine. Based on instantaneous assessment, mon-
telukast was superior to placebo with regards to several
outcome measures, such as TSS (p = 0.005) and number of
hives (p = 0.001), although pruritus and size of largest hives
did not show significant differences. Based on reflective
evaluation, there was no difference in interference with
sleep and the use of rescue medication (oral loratidine)
with montelukast, however benefit was shown with regards
to interference with daily activities (p = 0.002). All side
effects reported were mild.
Erbagci et al. [16] compared montelukast 10 mg daily vs.
placebo in a single-blind placebo-controlled cross-over
trial (n = 30). In this study, patients used the antihistamine
cetirizine on an ‘as required’ basis. Each treatment option
was given for 6 weeks with a 2 week washout period. All
patients completed the study. There was significant im-
provement in the UAS and weekly antihistamine count in
the montelukast group. No significant side effects were
reported attributable to the use of montelukast, and the
tolerability profile was the same as for placebo. Five female
patients developed transitory and mild headache.
A randomised double-blind placebo-controlled cross-
over study was conducted by Riemers et al. [17] compar-
ing zafirlukast 20 mg daily with placebo (n = 52). None of
Table 1 Summary of effects of LTRA in all studies
Outcome measure Studies LTRA vs Placebo LTRA + AH vs AH LTRA vs AH
Pruritus Di Lorenzo et al. ND ND Favours AH
Reimers et al. ND - -
Kosnik et al. - ND -
Nettis et al. [14] - Favours LTRA -
Godse - - Favours AH
Number of weals Di Lorenzo et al. Favours LTRA ND Favours AH
Reimers et al. ND - -
Kosnik et al. - ND -
Nettis et al. [14] - Favours LTRA -
Interference with sleep Di Lorenzo et al. ND ND Favours AH
Reimers et al. ND - -
Kosnik et al. - ND -
Interference with daily activities Di Lorenzo et al. Favours LTRA ND ND
Reimers et al. ND - -
Quality of life score Agcaoili et al. ND - -
Nettis et al. [14] - Favours LTRA -
TSS Di Lorenzo et al. Favours LTRA ND Favours AH
Nettis et al. [23] - - Favours LTRA
Size of weals Di Lorenzo et al. ND ND -
UAS Erbagci et al. Favours LTRA - -
Agcaoili et al. Favours LTRA - -
Kosnik et al. - ND -
Wan et al. - ND -
Godse - - Favours AH
Weekly AH count Erbagci et al. Favours LTRA - -
Visual analog scale Bagenstose et al. - Favours LTRA -
Nettis et al. - Favours LTRA -
Wan et al. - ND -
TES Bagenstose et al. - ND -
ND- no difference, AH- antihistamine, LTRA- leukotriene receptor antagonist, TSS – total symptom score, UAS- urticarial activity score, TES – treatment effectiveness score.
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(itching score, number of weals score, disturbance of sleep
score, disturbance of daily activity score and need of rescue
medication score) or by the physician (intensity of ery-
thema, number of weals, extension of weals, and size of
weals) showed statistically significant differences in either
group. No significant benefit was seen with zafirlukast even
when the subset of patients with symptoms aggravated by
pressure, NSAIDs or aspirin was considered. This is in
contrast to other studies, where LTRA showed evidence of
benefit in direct-pressure urticaria, [18] and food additive
or aspirin induced urticaria [19]. Nonetheless, treatment
with zafirlukast was well tolerated, with no clinical side
effects or significant changes in laboratory parameters.
Agcaoili et al. [12] in a randomised double blind study
published only in abstract form, compared montelukastto placebo in 29 patients with chronic urticaria. Outcome
measures were difference in the UAS and mean quality of
life score from baseline, on the second and fourth week of
treatment; overall outcome was defined as success or fail-
ure rates. UAS was significantly improved after two weeks,
and the quality of life score showed a trend towards im-
provement. Success rates were better with montelukast
after two weeks.
LTRA plus antihistamine vs. antihistamine alone
Bagenstose et al. [20] conducted a double-blind placebo-
controlled trial to assess the benefit of add-on LTRA, by
comparing cetrizine 10 mg daily plus zafirlukast 20 mg
twice a day vs. cetirizine 10 mg daily plus placebo, for three
weeks (n = 86). The study recruited only patients with
sub-optimal response to antihistamine therapy. Patient and
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fectiveness Score (TES), and number and size of lesions by
visual analogue scale (VAS) were evaluated at each weekly
visit for 3 weeks. VAS scores assessed by both patients and
physicians were significantly lower in the cetrizine plus
LTRA group. There were no significant adverse effects or
change in laboratory results in either groups.
The study by Di Lorenzo also compared combination
therapy vs. anti-histamine monotherapy as mentioned
above; combination therapy did not offer significant
benefit over monotherapy with desloratadine.
A cross-over double-blind study of 24 patients with
chronic urticaria whose symptoms were not adequately
alleviated by antihistamines was conducted by Kosnik et al.
[15] comparing montelukast 10 mg daily vs. placebo, in
addition to the patients’ usual antihistamine therapy. Each
treatment arm was continued for 2 weeks with a 7 day
washout period in between. There was no significant differ-
ence in total symptoms and medication scores between the
periods of placebo and montelukast use. A sub-group ana-
lysis of 5 patients with severe symptoms showed benefit
with montelukast when an in-house severity scale (calcu-
lated by summing up the pruritus score, number of weals
score and sleep disturbance score) was used; this benefit
was not demonstrated when a validated UAS was used.
A randomised double-blind placebo controlled study
was conducted by Nettis et al. [14] involving 81 patients,
of whom 5 discontinued treatment, resulting in an evalu-
able population of 76. Patients were randomized to receive
desloratadine 5 mg daily plus placebo, desloratadine 5 mg
daily plus montelukast 10 mg daily, or placebo only for six
weeks. This study demonstrated greater benefit with the
combination of desloratadine plus montelukast compared
to desloratadine alone in improving pruritus, number and
size of weals, quality of life, and VAS. Improvement in the
number of separate urticarial episodes did not show a sig-
nificant difference between the two groups. There were
no significant clinical, biochemical or electrocardiographic
adverse effects seen with LTRA use. The study was well
conducted and risk of bias was low, with clear details of
blinding and minimal loss to follow-up.
Wan et al. [21] performed a single blind randomised
controlled trial of 120 patients with newly diagnosed
chronic urticaria. After a 1 week washout period, patients
were randomised to four groups: oral hydroxyzine 25 mg +
cetirizine 5 mg twice a day, oral hydroxyzine 25 mg + famo-
tidine 20 mg twice a day, oral hydroxyzine 25 mg twice a
day +montelukast 5 mg twice a daily, and oral placebo
twice a day. The drop out rate among those receiving
placebo was high, as the patients did not experience benefit
(13 out of 30). UAS and a visual analog scale were used to
evaluate outcome. The efficacy of the combination of
antihistamine and LTRA was comparable with treatment
with dual antihistamine therapy, and superior to placebo.The main difficulty in interpreting this study from a clinical
perspective is that the comparison was with dual antihista-
mine therapy.
Leukotriene antagonist vs. antihistamine
Four studies provided head-to-head data comparing LTRA
vs. antihistamines [13,19,22,23]. The study by Di Lorenzo
et al. [13] included this comparison, and showed that
desloratadine had significantly greater efficacy compared
to montelukast with regard to TSS (mean difference 1.66,
95% CI 1.28- -1.05), pruritus (mean difference 0.7, 95%
CI-0.74- -0.66), number of hives (mean difference −0.21
95% CI −0.27- -0.16), size of largest hives (mean
difference −0.24 95% CI −0.29- -0.19) on reflective evalu-
ation. Similarly, on instantaneous evaluation of interference
with sleep and the use of rescue medication, desloratadine
was shown to be superior to montelukast, although this
benefit was not demonstrated with regards to interference
with daily activities.
Nettis et al. [23] compared montelukast with fexofena-
dine in patients with CIU in a double blind study involving
15 patients in montelukast and 12 patients in fexofenadine
group. The total symptom score was worse in the fexofe-
nadine group compared with the montelukast group.
However the reduction in time of symptomatic profile was
the same in both groups.
Godse [22] compared montelukast with cetrizine in
patients with CIU, in a randomised trial of 20 patients. The
outcome measure was improvement in UAS and severity of
itching at one week and two weeks after commencing
therapy. Results with montelukast were disappointing, with
8 of the 10 patients in the montelukast group reporting
worsening of itching and an increase in the UAS; 2 patients
were lost to follow-up. The study had to be terminated at
7 days as a result of patients demanding rescue medication
(i.e., cetrizine).
Conclusions
Our systematic review of randomized controlled trials
did not demonstrate strong clinical evidence to refute or
accept the practice of prescribing LTRA in patients with
chronic urticaria. Reduction in number of hives was seen
with LTRAs compared to placebo, although LTRA did
not show benefit for any of the other outcomes. Thus,
the use of LTRA alone for chronic urticaria is difficult to
justify based on current evidence.
Combined therapy of antihistamine with LTRA seems
to be beneficial according to most of the studies
[14,20,21] although one study gives contradictory re-
sults [13]. Head to head comparison of antihistamine
versus leukotriene antagonists also gives conflicting
data, and no firm conclusion can be made; overall it
appears that antihistamines are superior to LTRA. How-
ever there is very limited data on this.
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between the different groups was the wide variability of
outcome measures assessed. Even the cumulative scores
used to assess overall outcome had wide variation, which
is clearly shown in the study by Kosnik et al. [15] where
different results were obtained with the two in-house scor-
ing systems compared with the validated UAS. As a result,
data pooling for the purpose of meta-analysis was not pos-
sible. We attempted to obtain raw data by contacting the
authors, but were not successful despite repeated at-
tempts. Another limitation of our review is that because of
the wide heterogeneity in study populations, it is difficult
to ascertain if LTRA would be more beneficial in patients
with more severe, or refractory, chronic urticaria.
Overall, current evidence supports the use of LTRA in
combination with antihistamines, and the add-on effect of
LTRA in patients currently on antihistamines is likely to
be beneficial; this is in agreement with the 2009 treatment
guidelines [7]. LTRA cannot, however, be recommended
as single therapy for chronic urticaria. LTRA are also
significantly more costly, with one month’s treatment with
montelukast and zafirlukast costing about GBP 30 and 20
respectively while cetirizine costs just GBP 0.85 and
desloratadine costs GBP 7 for the same duration [24].
Importantly, LTRA appeared well tolerated with low
side effect profiles; this was demonstrated repeatedly in
nearly all trials. Thus, LTRA can be safely recommended
in combination with antihistamines in patients with
chronic urticaria who show inadequate response to anti-
histamines alone.
There is clearly a need for further studies. Future ran-
domized controlled studies should stratify patients based
on severity of chronic urticaria using standardized criteria.
Outcome measures should be carefully chosen, using
accepted and validated scales of measurement. Effects on
quality of life are an important outcome measure to be
considered. Studies should also be powered sufficiently to
evaluate the effect of benefit in subgroups of patients with
ASST positivity, food allergy, acetylsalicylic acid and
NSAID hypersensitivity. However this may not always be
feasible, thus alternately studies should use stringent
inclusion criteria to define the type of urticaria clearly, in
order to make comparisons and recommendations clearly.
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